AU2004283464B8 - Method of administering cationic liposomes comprising an active drug - Google Patents

Method of administering cationic liposomes comprising an active drug Download PDF

Info

Publication number
AU2004283464B8
AU2004283464B8 AU2004283464A AU2004283464A AU2004283464B8 AU 2004283464 B8 AU2004283464 B8 AU 2004283464B8 AU 2004283464 A AU2004283464 A AU 2004283464A AU 2004283464 A AU2004283464 A AU 2004283464A AU 2004283464 B8 AU2004283464 B8 AU 2004283464B8
Authority
AU
Australia
Prior art keywords
mole
paclitaxel
cationic
cancer
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004283464A
Other languages
English (en)
Other versions
AU2004283464B2 (en
AU2004283464A1 (en
Inventor
Kerstin Bartelheim
Christoph Brunner
Uwe Michaelis
Kurt Naujoks
Birgitta Sauer
Michael Teifel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syncore Biotechnology Co Ltd
Original Assignee
Syncore Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncore Biotechnology Co Ltd filed Critical Syncore Biotechnology Co Ltd
Publication of AU2004283464A1 publication Critical patent/AU2004283464A1/en
Application granted granted Critical
Publication of AU2004283464B2 publication Critical patent/AU2004283464B2/en
Publication of AU2004283464B8 publication Critical patent/AU2004283464B8/en
Assigned to SYNCORE BIOTECHNOLOGY CO., LTD reassignment SYNCORE BIOTECHNOLOGY CO., LTD Request for Assignment Assignors: MEDIGENE AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
AU2004283464A 2003-10-15 2004-10-15 Method of administering cationic liposomes comprising an active drug Ceased AU2004283464B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03023539 2003-10-15
EP03023539.4 2003-10-15
EP04000361 2004-01-09
EP04000361.8 2004-01-09
PCT/EP2004/011655 WO2005039533A1 (en) 2003-10-15 2004-10-15 Method of administering cationic liposomes comprising an active drug

Publications (3)

Publication Number Publication Date
AU2004283464A1 AU2004283464A1 (en) 2005-05-06
AU2004283464B2 AU2004283464B2 (en) 2011-03-17
AU2004283464B8 true AU2004283464B8 (en) 2011-04-14

Family

ID=34524705

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004283464A Ceased AU2004283464B8 (en) 2003-10-15 2004-10-15 Method of administering cationic liposomes comprising an active drug

Country Status (11)

Country Link
US (1) US20080063699A1 (https=)
EP (2) EP1673069B1 (https=)
JP (2) JP5645340B2 (https=)
AU (1) AU2004283464B8 (https=)
CA (1) CA2542217C (https=)
DK (1) DK2286794T3 (https=)
ES (1) ES2574231T3 (https=)
HU (1) HUE028648T2 (https=)
PL (1) PL2286794T3 (https=)
PT (1) PT2286794T (https=)
WO (1) WO2005039533A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
JP5700909B2 (ja) * 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトＭｅｄｉＧｅｎｅ ＡＧ パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
DK1919450T3 (da) * 2005-09-01 2014-09-15 Meda Ab Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
US20090232731A1 (en) * 2006-05-18 2009-09-17 Martin Funk Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
EP2598128B1 (en) 2010-07-28 2018-03-28 Life Technologies Corporation Anti- viral azide-containing compounds
US20140005160A1 (en) * 2010-12-01 2014-01-02 Hooshmand SHESHBARADARAN Method for Treating Refractory Cancer
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
SG11201404361UA (en) 2012-01-26 2014-09-26 Life Technologies Corp Methods for increasing the infectivity of viruses
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
CA2998483C (en) 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
EP4659741A1 (en) * 2023-01-31 2025-12-10 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of paclitaxel cationic liposome in treating tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017508A1 (en) * 1999-09-09 2001-03-15 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
WO2004002468A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
EP0706373B1 (en) 1992-03-23 2000-07-19 Georgetown University Liposome encapsulated taxol and a method of using the same
DE4447770C2 (de) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017508A1 (en) * 1999-09-09 2001-03-15 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system
WO2004002468A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Method of producing a cationic liposomal preparation comprising a lipophilic compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Australian Prescription Products Guide [APP2002] 31st Edition, ISSN 1321-9758, pages 3423-3426 in reference to Taxol. *

Also Published As

Publication number Publication date
JP5645340B2 (ja) 2014-12-24
HUE028648T2 (en) 2016-12-28
PT2286794T (pt) 2016-07-13
US20080063699A1 (en) 2008-03-13
EP2286794B8 (en) 2016-06-01
WO2005039533A1 (en) 2005-05-06
EP1673069B1 (en) 2016-10-12
EP2286794A1 (en) 2011-02-23
ES2574231T3 (es) 2016-06-16
CA2542217A1 (en) 2005-05-06
EP1673069A1 (en) 2006-06-28
AU2004283464B2 (en) 2011-03-17
DK2286794T3 (en) 2016-07-25
AU2004283464A1 (en) 2005-05-06
JP2012229255A (ja) 2012-11-22
PL2286794T3 (pl) 2016-10-31
CA2542217C (en) 2018-03-27
JP2007508353A (ja) 2007-04-05
EP2286794B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
AU2004283464B8 (en) Method of administering cationic liposomes comprising an active drug
US9827196B2 (en) Method of administering a cationic liposomal preparation
CA2922029C (en) A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
US7060828B2 (en) Liposomal camptothecins and uses thereof
AU2018205544B2 (en) Treatment of pancreatic cancer
CN108883068A (zh) 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法
AU2022308041A1 (en) Nanoparticles for cancer treatment
HK1123229B (en) Treatment of triple receptor negative breast cancer

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 25, NO 11, PAGE(S) 1345 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME MEDIGENE AG, APPLICAITON NO. 2004283464, UNDER INID (71) CORRECT THE APPLICANT NAME TO READ MEDI- GENE AG

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SYNCORE BIOTECHNOLOGY CO., LTD

Free format text: FORMER OWNER WAS: MEDIGENE AG

MK14 Patent ceased section 143(a) (annual fees not paid) or expired